Austria – more cash for vaccine designers


Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German MIG Fonds expanded an existing investment in their MIG11 portfolio with a further €5m. Both investors secured an option for further capital injections that could end up totalling €30m. Affiris CSO und co-founder Frank Mattner said: “We knew from the start that all stakeholders share a common understanding of where the journey of Affiris should take us.”
On the basis of its proprietary Affitom Technology, Affiris is developing vaccines for several indications, among them ones for Alzheimer’s, Parkinson’s, atherosclerosis and high blood pressure. Up to now, Affiris has pocketed about €12m from MIG – the only out-of-house investor on board since the firm was founded. In 2008, British drugmaker GlaxoSmithKline acquired the rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on Affiris‘ Affitope technology. These are currently in Phase I clinical development. The total potential value of the agreement could reach a430m. Last October, the Michael J. Fox Foundation announced that it was awarding €1.5m to Affiris for a clinical study of the Parkinson’s vaccine candidate Affitope PD01.



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...



Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues